KIORA PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
KIORA PHARMACEUTICALS, INC. (KPRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $13554.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-07
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $13554.00, a 42.30% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $23490.00, a 6172.36% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $374.50, a 26.95% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $295.00, a 4194.03% increase year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $22645.00, a 4975.87% increase from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $446.13, a 88.42% decline from fiscal 2023.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $3851.03, a 357.06% increase from fiscal 2022.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $842.57, a 19.45% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13554.00 10-Q · filed 2026-08-07 | |||||
| 2026-03-31 | $13554.00 10-Q · filed 2026-05-08 | |||||
| 2025-12-31 | $22645.00 10-K · filed 2026-03-25 | |||||
| 2025-09-30 | $22645.06 10-Q · filed 2025-11-07 | |||||
| 2025-06-30 | $23490.00 10-Q · filed 2025-08-08 | |||||
| 2025-03-31 | $23490.00 10-Q · filed 2025-05-09 | |||||
| 2024-12-31 | $446.13 10-K · filed 2026-03-25 | |||||
| 2024-09-30 | $1202.15 10-Q · filed 2024-11-08 | |||||
| 2024-06-30 | $980.89 10-Q · filed 2024-08-09 | |||||
| 2024-03-31 | $374.50 10-Q · filed 2024-05-10 | |||||
| 2023-12-31 | $3851.03 10-K · filed 2025-03-25 | $373.32 10-K · filed 2024-03-25 | ||||
| 2023-09-30 | $86.42 10-Q · filed 2023-11-09 | |||||
| 2023-06-30 | $295.00 10-Q · filed 2023-08-08 | |||||
| 2023-03-31 | $295.00 10-Q · filed 2023-05-09 | |||||
| 2022-12-31 | $842.57 10-K · filed 2024-03-25 | |||||
| 2022-09-30 | $447.05 10-Q · filed 2022-11-09 | |||||
| 2022-06-30 | $18.42 10-Q · filed 2022-08-12 | |||||
| 2022-03-31 | $6.87 10-Q · filed 2022-07-08 | |||||
| 2021-12-31 | $1046.00 10-K · filed 2023-03-23 | $25.86 10-K · filed 2022-04-15 | ||||
| 2021-09-30 | $454.83 10-Q · filed 2022-11-09 | $20.40 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $10.82 10-Q · filed 2022-08-12 | |||||
| 2021-03-31 | $10.83 10-Q · filed 2021-05-12 | |||||
| 2020-12-31 | $10.59 10-K/A · filed 2022-07-07 | |||||
| 2020-09-30 | $10.59 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $10.59 10-Q · filed 2021-08-12 | $10.59 10-Q · filed 2020-08-06 | ||||
| 2020-03-31 | $11.06 10-Q · filed 2021-05-12 | |||||
| 2019-12-31 | $28.58 10-K · filed 2021-03-25 | |||||
| 2019-09-30 | $16.25 10-Q · filed 2019-11-07 | |||||
| 2019-06-30 | $1.08 10-Q · filed 2019-08-08 | |||||
| 2019-03-31 | $16.25 10-Q · filed 2020-11-09 | |||||
| 2018-12-31 | $25.76 10-K · filed 2020-03-04 | |||||
| 2018-09-30 | $19.51 10-Q · filed 2019-11-07 | |||||
| 2018-06-30 | $0.80 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |